Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas
Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the N...
Uloženo v:
| Vydáno v: | Oncogene Ročník 29; číslo 47; s. 6216 - 6221 |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
25.11.2010
Nature Publishing Group |
| Témata: | |
| ISSN: | 0950-9232, 1476-5594, 1476-5594 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Biallelic inactivation of the
NF2
gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the
NF2
gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline
NF2
mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one
NF2
mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline
SMARCB1
mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline
SMARCB1
mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and
SMARCB1
-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in
SMARCB1
-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. |
|---|---|
| AbstractList | Biallelic inactivation of the
NF2
gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the
NF2
gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline
NF2
mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one
NF2
mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline
SMARCB1
mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline
SMARCB1
mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and
SMARCB1
-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in
SMARCB1
-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. [PUBLICATION ABSTRACT] Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. Oncogene (2010) 29, 6216-6221; doi: 10.1038/onc.2010.363; published online 23 August 2010 Keywords: mitotic recombination; schwannomatosis; SMARCB1; NF2; vestibular schwannoma Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context.Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in conjunction with either a second point mutation or loss of heterozygosity (LOH). We have performed DNA sequence and dosage analysis of the NF2 gene in a panel of 239 schwannoma tumours: 97 neurofibromatosis type 2 (NF2)-related schwannomas, 104 sporadic vestibular schwannomas (VS) and 38 schwannomatosis-related schwannomas. In total, we identified germline NF2 mutations in 86 out of 97 (89%) NF2 patients and a second mutational event in 77 out of 97 (79%). LOH was by far the most common form of second hit. A combination of microsatellite analysis with either conventional comparative genomic hybridization (CGH) or multiplex ligation-dependent probe amplification (MLPA) identified mitotic recombination (MR) as the cause of LOH in 14 out of 72 (19%) total evaluable tumours. Among sporadic VS, at least one NF2 mutation was identified by sequence analysis or MLPA in 65 out of 98 (66%) tumours. LOH occurred in 54 out of 96 (56%) evaluable tumours, but MR only accounted for 5 out of 77 (6%) tested. LOH was present in 28 out of 34 (82%) schwannomatosis-related schwannomas. In all eight patients who had previously tested positive for a germline SMARCB1 mutation, this involved loss of the whole, or part of the long arm, of chromosome 22. In contrast, 5 out of 22 (23%) tumours from patients with no germline SMARCB1 mutation exhibited MR. High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine the chromosomal breakpoint locations in tumours with MR. A range of unique recombination sites, spanning approximately 11.4 Mb, were identified. This study shows that MR is a mechanism of LOH in NF2 and SMARCB1-negative schwannomatosis-related schwannomas, occurring less frequently in sporadic VS. We found no evidence of MR in SMARCB1-positive schwannomatosis, suggesting that susceptibility to MR varies according to the disease context. |
| Audience | Academic |
| Author | Smith, M J Trump, D Newman, W G Hadfield, K D Bowers, N L Rutherford, S A Urquhart, J E Evans, D G King, A T Wallace, A J |
| Author_xml | – sequence: 1 givenname: K D surname: Hadfield fullname: Hadfield, K D organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester – sequence: 2 givenname: M J surname: Smith fullname: Smith, M J organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester – sequence: 3 givenname: J E surname: Urquhart fullname: Urquhart, J E organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester – sequence: 4 givenname: A J surname: Wallace fullname: Wallace, A J organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester – sequence: 5 givenname: N L surname: Bowers fullname: Bowers, N L organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester – sequence: 6 givenname: A T surname: King fullname: King, A T organization: Department of Neurosurgery, Hope Hospital – sequence: 7 givenname: S A surname: Rutherford fullname: Rutherford, S A organization: Department of Neurosurgery, Hope Hospital – sequence: 8 givenname: D surname: Trump fullname: Trump, D organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester – sequence: 9 givenname: W G surname: Newman fullname: Newman, W G organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester – sequence: 10 givenname: D G surname: Evans fullname: Evans, D G email: gareth.evans@cmft.nhs.uk organization: Department of Genetic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, University of Manchester |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23629989$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20729918$$D View this record in MEDLINE/PubMed |
| BookMark | eNqF0stu1DAUBmALFdFpYccaRaCKTTM4viT2sqpaQKpAQrCOHMeeukrswXaKhnfgnTlzgSlVK5SF5eQ75zjWf4QOfPAGoZcVnleYinfB6znBsKM1fYJmFWvqknPJDtAMS45LSSg5REcp3WCMG4nJM3RIcEOkrMQM_fqisklFsMUQ0ma9NtnE8HO1CMnlVaF8X4wuh-x0EY0OY-e8yi74wvni0yUpkr7-obwPo0qnRVqGqHqgtyZl102DinfBptt-n2FEuvv9OXpq1ZDMi916jL5dXnw9_1BefX7_8fzsqtS8EbmUteolqZTUpLed1pIILi01VAmlRUWlMoKI3krcCEoVq23T47rjXDOuObH0GL3d9l3G8H2Co7ajS9oMg_ImTKkVNZOc1kT8X1aM1QwzDPL1PXkTpujhNwDxinIh1ujNY4jUrII2tSB7tVCDaZ23IUel14PbM8IoJ4AYqPkDCp7ejE5DSKyD9_8UvNoNn7rR9O0yulHFVfsnDQBOdkAlrQYbldcu7R3ciJRCgjvdOh0hNNHYv6TC7TqULYSyXYeyhVACJ_e4dnmTITiwGx4rKrdFCXr7hYn7m3rQ_wao4_Nf |
| CODEN | ONCNES |
| CitedBy_id | crossref_primary_10_1002_ajmg_a_34359 crossref_primary_10_1038_s41598_017_05769_0 crossref_primary_10_1038_s41467_017_00346_5 crossref_primary_10_1016_j_modpat_2024_100427 crossref_primary_10_1097_MAO_0000000000002096 crossref_primary_10_1038_cdd_2016_54 crossref_primary_10_1038_s41598_018_23609_7 crossref_primary_10_3390_cancers16213639 crossref_primary_10_3390_diagnostics12051044 crossref_primary_10_1016_j_wneu_2018_06_010 crossref_primary_10_1007_s00401_016_1583_8 crossref_primary_10_3390_cancers12040835 crossref_primary_10_1007_s00405_012_2269_z crossref_primary_10_1093_neuonc_noab287 crossref_primary_10_1093_neuonc_nor101 crossref_primary_10_1016_j_survophthal_2016_08_002 crossref_primary_10_1097_MAO_0000000000002613 crossref_primary_10_1093_neuonc_not242 crossref_primary_10_3171_2014_6_JNS131433 crossref_primary_10_1093_brain_awac478 crossref_primary_10_1097_PAS_0b013e31825798f1 crossref_primary_10_1186_s12920_021_01049_z crossref_primary_10_1097_NEN_0000000000000238 crossref_primary_10_1097_MAO_0000000000004163 crossref_primary_10_1016_j_neuchi_2015_03_012 crossref_primary_10_1155_2012_856157 crossref_primary_10_1016_j_clineuro_2018_12_004 crossref_primary_10_3171_2020_3_JNS193230 crossref_primary_10_1053_j_semdp_2021_03_003 crossref_primary_10_1007_s40487_024_00279_2 crossref_primary_10_1007_s00428_012_1342_8 crossref_primary_10_1097_MAO_0000000000001932 crossref_primary_10_3390_cancers17010064 crossref_primary_10_1111_jop_12337 crossref_primary_10_1002_ajmg_a_34376 crossref_primary_10_1007_s11060_019_03176_1 crossref_primary_10_1097_PAS_0b013e31824d3155 crossref_primary_10_3390_ijms22115850 crossref_primary_10_1007_s40136_014_0061_x crossref_primary_10_4103_1673_5374_211172 crossref_primary_10_1038_cddiscovery_2015_21 crossref_primary_10_1007_s00439_016_1753_8 crossref_primary_10_1093_mutage_gew003 crossref_primary_10_1186_s40478_014_0082_1 crossref_primary_10_1136_jmedgenet_2020_107022 crossref_primary_10_1371_journal_pone_0252048 crossref_primary_10_1186_s12935_019_0989_5 crossref_primary_10_1093_neuonc_nou317 crossref_primary_10_3389_fneur_2019_00978 crossref_primary_10_1186_s12920_015_0076_2 crossref_primary_10_1371_journal_pone_0065868 crossref_primary_10_1007_s11010_014_2011_9 crossref_primary_10_1038_s41598_023_33812_w crossref_primary_10_1097_MAO_0b013e318298ac79 crossref_primary_10_3892_ijo_2013_1798 crossref_primary_10_1002_gcc_22338 crossref_primary_10_3892_or_2014_3526 crossref_primary_10_1038_s41416_022_01955_8 crossref_primary_10_1016_j_cancergen_2014_04_001 crossref_primary_10_1177_1535370213480744 crossref_primary_10_1371_journal_pone_0030418 crossref_primary_10_3390_cancers17030393 crossref_primary_10_1007_s12253_013_9644_y crossref_primary_10_1111_cge_13099 crossref_primary_10_3390_cells10071840 crossref_primary_10_1016_j_ebiom_2018_09_042 crossref_primary_10_1007_s10048_011_0300_y crossref_primary_10_1002_ajmg_a_35760 crossref_primary_10_1111_nan_12330 crossref_primary_10_1007_s10689_025_00486_4 crossref_primary_10_1097_MAO_0000000000000788 crossref_primary_10_1186_s40478_025_01937_w crossref_primary_10_1007_s11060_016_2150_9 crossref_primary_10_1212_WNL_0000000000001129 crossref_primary_10_1002_1878_0261_12307 crossref_primary_10_1007_s00439_018_1909_9 |
| Cites_doi | 10.1038/990031 10.1086/513207 10.1038/sj.bjc.6990691 10.1136/jmg.2007.056499 10.1038/90148 10.1136/jmg.24.2.65 10.1371/journal.pgen.1000538 10.1111/j.1399-0004.2008.01060.x 10.1046/j.1365-2443.2001.00432.x 10.1212/01.WNL.0000070184.08740.E0 10.1007/BF02259711 10.1002/gcc.20353 10.1086/302343 10.1002/humu.20679 10.1136/jmg.40.11.802 |
| ContentType | Journal Article |
| Copyright | Macmillan Publishers Limited 2010 2015 INIST-CNRS COPYRIGHT 2010 Nature Publishing Group Macmillan Publishers Limited 2010. Copyright Nature Publishing Group Nov 25, 2010 |
| Copyright_xml | – notice: Macmillan Publishers Limited 2010 – notice: 2015 INIST-CNRS – notice: COPYRIGHT 2010 Nature Publishing Group – notice: Macmillan Publishers Limited 2010. – notice: Copyright Nature Publishing Group Nov 25, 2010 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7TM 7TO 7U9 7X7 7XB 88A 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M7P MBDVC P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U RC3 7X8 7TK |
| DOI | 10.1038/onc.2010.363 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database ProQuest Research Library Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic ProQuest SciTech Collection ProQuest Medical Library ProQuest Central (Alumni) MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | Research Library Prep Research Library Prep Genetics Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology |
| EISSN | 1476-5594 |
| EndPage | 6221 |
| ExternalDocumentID | 2201482641 A243526824 20729918 23629989 10_1038_onc_2010_363 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom |
| GeographicLocations_xml | – name: United Kingdom |
| GroupedDBID | --- -Q- 0R~ 123 29N 2WC 36B 39C 3O- 3V. 4.4 406 53G 5RE 70F 7X7 88A 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AANZL AAYZH AAZLF ABAKF ABAWZ ABDBF ABJNI ABLJU ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACPRK ACRQY ACUHS ACZOJ ADBBV ADFRT ADHDB AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFKRA AFSHS AGHAI AGQEE AHMBA AHSBF AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 DWQXO E3Z EAD EAP EBC EBD EBLON EBS EE. EIOEI EJD EMB EMK EMOBN EPL ESX F5P FDQFY FEDTE FERAY FIZPM FRP FSGXE FYUFA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IAO IHR INH INR ITC IWAJR JSO JZLTJ KQ8 L7B LK8 M0L M1P M2O M7P N9A NAO NQJWS NXXTH O9- OK1 OVD P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TSG TUS UKHRP W2D WH7 ~8M AASML AATNV AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEFQL AEZWR AFDZB AFFHD AFHIU AHWEU AIGIU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB .55 .GJ AACDK ABEFU AFFNX BAWUL FIGPU IQODW LGEZI LOTEE NADUK RNS TR2 UDS X7M ZXP CGR CUY CVF ECM EIF NPM 7TM 7TO 7U9 7XB 8FD 8FK FR3 H94 K9. MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U RC3 7X8 PUEGO 7TK |
| ID | FETCH-LOGICAL-c578t-96ad921a9c2dfbcc92859f3e3a8ac8139ae828df907833a46f7d06b55c45c52f3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 88 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000284601700003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0950-9232 1476-5594 |
| IngestDate | Thu Oct 02 17:48:37 EDT 2025 Thu Oct 02 11:16:40 EDT 2025 Tue Nov 04 00:18:16 EST 2025 Tue Oct 07 06:01:06 EDT 2025 Sat Nov 29 13:59:02 EST 2025 Sat Nov 29 10:39:02 EST 2025 Mon Jul 21 05:53:21 EDT 2025 Mon Jul 21 09:12:16 EDT 2025 Sat Nov 29 03:40:50 EST 2025 Tue Nov 18 21:00:17 EST 2025 Fri Feb 21 02:38:25 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 47 |
| Keywords | mitotic recombination schwannomatosis vestibular schwannoma Nervous system diseases SMARCB1 Mitotic recombination Sporadic Neurinoma Loss of heterozygosity Benign neoplasm NF2 Carcinogenesis |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c578t-96ad921a9c2dfbcc92859f3e3a8ac8139ae828df907833a46f7d06b55c45c52f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 20729918 |
| PQID | 2641403682 |
| PQPubID | 36330 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_864953628 proquest_miscellaneous_814464040 proquest_journals_815135880 proquest_journals_2641403682 gale_infotracmisc_A243526824 gale_infotracacademiconefile_A243526824 pubmed_primary_20729918 pascalfrancis_primary_23629989 crossref_primary_10_1038_onc_2010_363 crossref_citationtrail_10_1038_onc_2010_363 springer_journals_10_1038_onc_2010_363 |
| PublicationCentury | 2000 |
| PublicationDate | 20101125 |
| PublicationDateYYYYMMDD | 2010-11-25 |
| PublicationDate_xml | – month: 11 year: 2010 text: 20101125 day: 25 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: Basingstoke – name: England – name: New York |
| PublicationTitle | Oncogene |
| PublicationTitleAbbrev | Oncogene |
| PublicationTitleAlternate | Oncogene |
| PublicationYear | 2010 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Kino, Takeshima, Nakao, Nishi, Yamamoto, Kimura (CR13) 2001; 6 Sestini, Bacci, Provenzano, Genuardi, Papi (CR16) 2008; 29 Evans, Huson, Donnai, Neary, Blair, Newton (CR6) 1992; 84 Gonzalez-Gomez, Bello, Alonso, Lomas, Arjona, Campos (CR7) 2003; 9 Hulsebos, Plomp, Wolterman, Robanus-Maandag, Baas, Wesseling (CR9) 2007; 80 Serra, Rosenbaum, Nadal, Winner, Ars, Estivill (CR15) 2001; 28 Kaplan, Aurias, Julier, Prieur, Szajnert (CR12) 1987; 24 Boyd, Smith, Kluwe, Balogh, Maccollin, Plotkin (CR1) 2008; 74 Carbone, Harris, Vessere, Mootnick, Humphray, Rogers (CR2) 2009; 5 Dunham, Shimizu, Roe, Chissoe, Hunt, Collins (CR4) 1999; 402 James, Varley (CR10) 1996; 4 De Raedt, Maertens, Chmara, Brems, Heyns, Sciot (CR3) 2006; 45 MacCollin, Willett, Heinrich, Jacoby, Acierno (CR14) 2003; 60 Hadfield, Newman, Bowers, Wallace, Bolger, Colley (CR8) 2008; 45 Edelmann, Pandita, Morrow (CR5) 1999; 64 Warren, James, Ramsden, Wallace, Baser, Varley (CR17) 2003; 40 James, Kelsey, Birch, Varley (CR11) 1999; 81 P Gonzalez-Gomez (BFonc2010363_CR7) 2003; 9 DG Evans (BFonc2010363_CR6) 1992; 84 E Serra (BFonc2010363_CR15) 2001; 28 KD Hadfield (BFonc2010363_CR8) 2008; 45 T Kino (BFonc2010363_CR13) 2001; 6 LA James (BFonc2010363_CR11) 1999; 81 C Warren (BFonc2010363_CR17) 2003; 40 T De Raedt (BFonc2010363_CR3) 2006; 45 M MacCollin (BFonc2010363_CR14) 2003; 60 I Dunham (BFonc2010363_CR4) 1999; 402 R Sestini (BFonc2010363_CR16) 2008; 29 TJ Hulsebos (BFonc2010363_CR9) 2007; 80 L Carbone (BFonc2010363_CR2) 2009; 5 L James (BFonc2010363_CR10) 1996; 4 C Boyd (BFonc2010363_CR1) 2008; 74 JC Kaplan (BFonc2010363_CR12) 1987; 24 L Edelmann (BFonc2010363_CR5) 1999; 64 |
| References_xml | – volume: 402 start-page: 489 year: 1999 end-page: 495 ident: CR4 article-title: The DNA sequence of human chromosome 22 publication-title: Nature doi: 10.1038/990031 – volume: 80 start-page: 805 year: 2007 end-page: 810 ident: CR9 article-title: Germline mutation of INI1/SMARCB1 in familial schwannomatosis publication-title: Am J Hum Genet doi: 10.1086/513207 – volume: 81 start-page: 300 year: 1999 end-page: 304 ident: CR11 article-title: Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization publication-title: Br J Cancer doi: 10.1038/sj.bjc.6990691 – volume: 45 start-page: 332 year: 2008 end-page: 339 ident: CR8 article-title: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis publication-title: J Med Genet doi: 10.1136/jmg.2007.056499 – volume: 28 start-page: 294 year: 2001 end-page: 296 ident: CR15 article-title: Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas publication-title: Nat Genet doi: 10.1038/90148 – volume: 84 start-page: 603 year: 1992 end-page: 618 ident: CR6 article-title: A clinical study of type 2 neurofibromatosis publication-title: Q J Med – volume: 24 start-page: 65 year: 1987 end-page: 78 ident: CR12 article-title: Human chromosome 22 publication-title: J Med Genet doi: 10.1136/jmg.24.2.65 – volume: 5 start-page: e1000538 year: 2009 ident: CR2 article-title: Evolutionary breakpoints in the gibbon suggest association between cytosine methylation and karyotype evolution publication-title: PLoS Genet doi: 10.1371/journal.pgen.1000538 – volume: 74 start-page: 358 year: 2008 end-page: 366 ident: CR1 article-title: Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis publication-title: Clin Genet doi: 10.1111/j.1399-0004.2008.01060.x – volume: 6 start-page: 441 year: 2001 end-page: 454 ident: CR13 article-title: Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma publication-title: Genes Cells doi: 10.1046/j.1365-2443.2001.00432.x – volume: 60 start-page: 1968 year: 2003 end-page: 1974 ident: CR14 article-title: Familial schwannomatosis: exclusion of the NF2 locus as the germline event publication-title: Neurology doi: 10.1212/01.WNL.0000070184.08740.E0 – volume: 4 start-page: 163 year: 1996 end-page: 164 ident: CR10 article-title: Preparation, labelling and detection of DNA from archival tissue sections suitable for comparative genomic hybridization publication-title: Chromosome Res doi: 10.1007/BF02259711 – volume: 45 start-page: 893 year: 2006 end-page: 904 ident: CR3 article-title: Somatic loss of wild type NF1 allele in neurofibromas: Comparison of NF1 microdeletion and non-microdeletion patients publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20353 – volume: 9 start-page: 5601 year: 2003 end-page: 5606 ident: CR7 article-title: CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas publication-title: Clin Cancer Res – volume: 64 start-page: 1076 year: 1999 end-page: 1086 ident: CR5 article-title: Low-copy repeats mediate the common 3-Mb deletion in patients with velo-cardio-facial syndrome publication-title: Am J Hum Genet doi: 10.1086/302343 – volume: 29 start-page: 227 year: 2008 end-page: 231 ident: CR16 article-title: Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas publication-title: Hum Mutat doi: 10.1002/humu.20679 – volume: 40 start-page: 802 year: 2003 end-page: 806 ident: CR17 article-title: Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation publication-title: J Med Genet doi: 10.1136/jmg.40.11.802 – volume: 74 start-page: 358 year: 2008 ident: BFonc2010363_CR1 publication-title: Clin Genet doi: 10.1111/j.1399-0004.2008.01060.x – volume: 40 start-page: 802 year: 2003 ident: BFonc2010363_CR17 publication-title: J Med Genet doi: 10.1136/jmg.40.11.802 – volume: 84 start-page: 603 year: 1992 ident: BFonc2010363_CR6 publication-title: Q J Med – volume: 45 start-page: 893 year: 2006 ident: BFonc2010363_CR3 publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20353 – volume: 60 start-page: 1968 year: 2003 ident: BFonc2010363_CR14 publication-title: Neurology doi: 10.1212/01.WNL.0000070184.08740.E0 – volume: 29 start-page: 227 year: 2008 ident: BFonc2010363_CR16 publication-title: Hum Mutat doi: 10.1002/humu.20679 – volume: 64 start-page: 1076 year: 1999 ident: BFonc2010363_CR5 publication-title: Am J Hum Genet doi: 10.1086/302343 – volume: 81 start-page: 300 year: 1999 ident: BFonc2010363_CR11 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6990691 – volume: 45 start-page: 332 year: 2008 ident: BFonc2010363_CR8 publication-title: J Med Genet doi: 10.1136/jmg.2007.056499 – volume: 5 start-page: e1000538 year: 2009 ident: BFonc2010363_CR2 publication-title: PLoS Genet doi: 10.1371/journal.pgen.1000538 – volume: 402 start-page: 489 year: 1999 ident: BFonc2010363_CR4 publication-title: Nature doi: 10.1038/990031 – volume: 80 start-page: 805 year: 2007 ident: BFonc2010363_CR9 publication-title: Am J Hum Genet doi: 10.1086/513207 – volume: 9 start-page: 5601 year: 2003 ident: BFonc2010363_CR7 publication-title: Clin Cancer Res – volume: 4 start-page: 163 year: 1996 ident: BFonc2010363_CR10 publication-title: Chromosome Res doi: 10.1007/BF02259711 – volume: 24 start-page: 65 year: 1987 ident: BFonc2010363_CR12 publication-title: J Med Genet doi: 10.1136/jmg.24.2.65 – volume: 28 start-page: 294 year: 2001 ident: BFonc2010363_CR15 publication-title: Nat Genet doi: 10.1038/90148 – volume: 6 start-page: 441 year: 2001 ident: BFonc2010363_CR13 publication-title: Genes Cells doi: 10.1046/j.1365-2443.2001.00432.x |
| SSID | ssj0007902 |
| Score | 2.3253798 |
| Snippet | Biallelic inactivation of the
NF2
gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in... Biallelic inactivation of the NF2 gene occurs in the majority of schwannomas. This usually involves a combination of a point mutation or multiexon deletion, in... |
| SourceID | proquest gale pubmed pascalfrancis crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6216 |
| SubjectTerms | 631/208/68 692/699/67/1922 Acoustic neuroma Adolescent Adult Apoptosis Biological and medical sciences Cancer Cell Biology Cell division Cell physiology Cell transformation and carcinogenesis. Action of oncogenes and antioncogenes Child Chromosome 22 Chromosome Breakpoints Copy number Fundamental and applied biological sciences. Psychology Gene deletion Gene Dosage - genetics Gene mutations Genes, Neurofibromatosis 2 Genetic aspects Genetic disorders Genotype & phenotype Genotyping Health aspects Heterozygosity Homozygote Human Genetics Humans Hybridization Internal Medicine Loss of heterozygosity Loss of Heterozygosity - genetics Medical sciences Medicine Medicine & Public Health Mitosis - genetics Molecular and cellular biology Mutation Nervous system Neurilemmoma - genetics Neurofibromatoses - genetics Neurofibromatosis Neurofibromatosis 2 Neurofibromatosis 2 - genetics Neurofibromin 2 Neurological disorders Neurology Nucleotide sequence Oncology original-article Point mutation Polymorphism, Single Nucleotide - genetics Recombination Recombination, Genetic - genetics Risk factors Schwann cells Sequence analysis Single nucleotide polymorphisms Skin Neoplasms - genetics Tumors Tumors of the nervous system. Phacomatoses Vestibular system Young Adult |
| Title | Rates of loss of heterozygosity and mitotic recombination in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis schwannomas |
| URI | https://link.springer.com/article/10.1038/onc.2010.363 https://www.ncbi.nlm.nih.gov/pubmed/20729918 https://www.proquest.com/docview/2641403682 https://www.proquest.com/docview/815135880 https://www.proquest.com/docview/814464040 https://www.proquest.com/docview/864953628 |
| Volume | 29 |
| WOSCitedRecordID | wos000284601700003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: M7P dateStart: 19970101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: 7X7 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: BENPR dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest research library customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: M2O dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1476-5594 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0007902 issn: 0950-9232 databaseCode: 8C1 dateStart: 19970101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db5swED-t7b6kaR_pPli7yA_7eNhQwTZgnqYuarSXZlG1SXlDxsBaqYWsSTdl_8P-590ZkzRq15dJCITusDE-znfcjzuA1-hylFxHhZ_wivtSFfjOVXnghzoqRZjjAsQLW2wiGY3UZJKO3Qe3mYNVdjrRKuqiMfSNfA8XbkotFyv-cfrDp6pRFF11JTQ2YIuyJAgL3RsvNXHSYg7Righ8NGS4A74HQu01tWlxXSIWa0uSU8wPpnqGD6lqq1tcZ35eCZ3aFWn46H_H8hgeOluU7bfC8wRulXUP7rTVKRc9uDfoisH14O6hi8Fvw58jMk9ZU7FTHA0djwlS0_xefCcA2ILpumBnqCiwVUb-9hk633b-2UnNRkPO0KH-peuakEkfGLnVGttmNt9HTqjYywy2tdX5HLuYXaY_hW_Dg6-Dz74r6uAbVA5zP411kfJQp4YXVW5MShn0KlEKrbRRaI_qEp3Aokopvii0jKukCOI8ioyMTMQr8Qw266YuXwArjNR5GuQyLmOZ4xZVmv4DTqJc6FBqD95385oZl_GcCm-cZjbyLlSGUpCRFGQoBR68WXJP20wf_-B7RyKSkQLA1ox2_zHgPVEqrWyfS6o5oLj0YHeNE6fMrJH7a0K27JWjUYFecIrXd-KTOc0yy1ay48HOVbJCC05EqJQ9YEsqdUxYurpsLohFylii8r6BJSbYccyVB89baV_dHKWaT0OkvO3Ef9X7dc_r5c2j2IH7FpARhj6PdmFzfn5RvoLb5uf8ZHbeh41kkti9wr0ahH3Y-nQwGh_h2SH_0rfv-19NFlkd |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aAzYkxKXjEjaGHxg8QLTGdhLnAaFpUG3aVk1oSHszjpOwSltSlo6p_Af-Cr-Rc3JpV23sbQ9IlarqnNqJfW62P58D8BqXHCk3fuKGPOOuVAnqXBZ3Xc_4qfBidEA8qYpNhP2-OjyM9ufgT3sXhmCVrU2sDHVSWNojX0fHTanlAsU_Dn-4VDWKTlfbEhq1WOyk43NcspUftj_h_K5x3vt8sLnlNlUFXIvSOXKjwCQR90xkeZLF1kaUwi0TqTDKWIUBkUlxFZJkER1wCSODLEy6Qez7VvrW55nAdm_BbQwjuKqggvsTyx_WGEeMWrouBk68Adp3hVovclvjyEQgZlxg4wjuD02Jk5LV1TSuCncvHdVWHrD38H8bu0fwoIm12UatHI9hLs07cLeuvjnuwOJmW-yuAwt7DcZgCX5_ofCbFRk7xtGj7yOCDBW_xt8J4DZmJk_YCRpCbJXRfsJJPKi3VNkgZ_0eZ6U9Ojd5Tsir94y2DQy2zap8JjGhfi8yVK1Nf4-wi_Ii_Ql8vZEhegrzeZGnz4ElVpo46sYySAMZ48fPDN1zDv1YGE8aB961cqRtk9GdCosc6wpZIJRGqdMkdRqlzoG1CfewzmTyD763JJKaDBy2Zk1zTwOfiVKF6Q0uqaaC4tKBlRlOnDI7Q16dEepJrxyDJlzlR_j_Vlx1YzlLPZVVB5YvkxVGqMJHp-MAm1CpY8IK5mlxRixSBhKd0zUsAcGqA64ceFZr1_ThKJV-5CHlTatu096vGq8X17_FK1jcOtjb1bvb_Z1luFeBTzzP5f4KzI9Oz9KXcMf-HA3K09XKljD4dtMK-BfuBLGO |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aAwYS4lJuYWP4gcEDRE1s5_aA0NRRMQ2qCTFpb8FxYlZpS8rSMZX_wB_i13FOLs2qjb3tAalSVZ1TO7HPzfbncwBe4pIj48pL7YAbbsswRZ0ziWO7ysuEm6AD4mlVbCIYjcL9_Wh3Cf60d2EIVtnaxMpQp4WmPfI-Om5KLeeHvG8aWMTu1vD95IdNFaTopLUtp1GLyE42O8XlW_luewvneoPz4Yevg492U2HA1iipUzvyVRpxV0WapybROqJ0bkZkQoVKhxgcqQxXJKmJ6LBLKOmbIHX8xPO09LTHjcB2r8H1QKAU0y31QQcvCWq8I0Ywjo1BFG9A944I-0Wua0yZ8MWCO2ycwp2JKnGCTF1Z46LQ99yxbeUNh_f-53G8D3ebGJxt1krzAJayvAc366qcsx7cGrRF8Hqw8rnBHjyE318oLGeFYYc4kvR9QFCi4tfsOwHfZkzlKTtCA4mtMtpnOErG9VYrG-dsNOSs1AenKs8JkfWW0XaCwrZZleckITTwWYaqte73FLsoz9Ifwd6VDNFjWM6LPHsKLNVSJZGTSD_zZYIfzyi6_xx4iVCuVBa8aWUq1k2mdyo4chhXiAMRxiiBMUlgjBJowcace1JnOPkH32sSz5gMH7amVXN_A5-JUojFm1xSrYWQSwvWFjhxyvQCeX1BwOe9cgymcPUf4f9b0Y0bi1rGndxasHqeHGLkKjx0RhawOZU6JgxhnhUnxCKlL9FpXcLiE9za56EFT2pN6x6OUuxHLlJetarX9X7ReD27_C1ewArqXfxpe7SzCrcrTIrr2txbg-Xp8Un2HG7on9NxebxemRUG365a__4CzDG6BA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rates+of+loss+of+heterozygosity+and+mitotic+recombination+in+NF2+schwannomas%2C+sporadic+vestibular+schwannomas+and+schwannomatosis+schwannomas&rft.jtitle=Oncogene&rft.au=Hadfield%2C+K+D&rft.au=Smith%2C+M+J&rft.au=Urquhart%2C+J+E&rft.au=Wallace%2C+A+J&rft.date=2010-11-25&rft.issn=0950-9232&rft.volume=29&rft.issue=47&rft.spage=6216&rft.epage=6221&rft_id=info:doi/10.1038%2Fonc.2010.363&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon |